Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation

Mise à jour : Il y a 4 ans
Référence : NCT00408473

Femme et Homme

Extrait

The purpose of the study is to assess the efficacy of flecainide controlled release (CR) in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode.


Critère d'inclusion

  • Atrial fibrillation


Liens